Clinical trials: Persons With Psychiatric Disorders
- Condition Persons With Psychiatric Disorders
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Dementia, Vascular, Alzheimer Disease
LEAD IT! An App to Enable Persons With Early Stage Dementia to Lead Group Activities for Their Peers
The proposed Phase 2 project will involve the further development and evaluation of LEAD IT!, which is a tablet-based app designed to enable persons with dementia to lead activities for their peers (i.e., other persons with…
- Conditions
- Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
- Trial name
- NCT05516342
- Testing
- LEAD IT! Programming
- Where
- United States
- Volunteers
- 182 people
- Sponsor
- Hopeful Aging
Alzheimer's Disease
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
This is a randomized, double-blind, placebo-controlled first-in-human, Phase 1, safety, tolerability, pharmacokinetic (PK) and preliminary exploratory activity study of escalating multiple intravenous (IV) doses of IBC-Ab002 in…
- Trial name
- NCT05551741
- Testing
- IBC-Ab002
- Where
- 10 sites in Israel, Netherlands and 1 more
- Volunteers
- 40 people
- Sponsor
- Immunobrain Checkpoint
Posttraumatic Stress Disorder
MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder
The goal of this clinical trial is to compare MDMA-assisted therapy to placebo with therapy in people with chronic, treatment-resistant posttraumatic stress disorder (PTSD).
- Trial name
- NCT00090064
- Testing
- Midomafetamine HCl, Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Resilient Pharmaceuticals
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been…
- Trial name
- NCT04115319
- Testing
- SEP363856, quetiapine XR
- Where
- 42 sites in United States, Romania and 2 more
- Volunteers
- 305 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication
This study evaluated how well SEP-363856 works and how safe it is in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05628103
- Testing
- SEP-363856
- Where
- 25 sites in United States
- Volunteers
- 101 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Depressive Disorder, Major
A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression
This study is open to adults with depression (major depressive disorder) for whom standard treatment with antidepressants alone does not work sufficiently.
- Trial name
- NCT04521478
- Testing
- BI 1358894, Quetiapine
- Where
- 120 sites in United States, Argentina and 12 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Posttraumatic Stress Disorder (PTSD)
Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective in people with chronic, treatment-resistant PTSD.
- Trial name
- NCT01689740
- Testing
- Full Dose MDMA-assisted therapy (125 mg), Open-Label Full Dose MDMA-assisted therapy (125 mg), Psychotherapy
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- Resilient Pharmaceuticals
Borderline Personality Disorder
A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder
This study is open to adults with borderline personality disorder. The purpose of this study is to find out whether a medicine called BI 1358894 helps to reduce symptoms in people with borderline personality disorder.
- Trial name
- NCT04566601
- Testing
- BI 1358894
- Where
- 67 sites in United States, Argentina and 13 more
- Volunteers
- 390 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04092686
- Testing
- SEP-363856 75mg, SEP-363856 100mg
- Where
- 53 sites in United States, Bulgaria and 5 more
- Volunteers
- 464 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Narcolepsy
A Study to Collect Information of People With Narcolepsy in Spain
This study aims to review information of people with a sleep condition called narcolepsy. Narcolepsy is a condition that causes extreme sleepiness during the day including falling asleep suddenly.
- Trial name
- SOMNUS (NCT04667338)
- Where
- Spain
- Volunteers
- 214 people
- Sponsor
- Takeda
Sleep Disorders, Circadian Rhythm, Cognitive Dysfunction
Feasibility Study on the Use of Redormin®500 on Day-time Cognition
Randomized, double-blind, parallel groups, placebo-controlled, baseline/run-in period of 21 days followed by trial period of 21 days, digital phenotyping (sleep, cognitive/psychological parameters and HRV).
- Trial name
- NCT05684523
- Testing
- Valerian-Hop Extract
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Max Zeller Soehne AG
Posttraumatic Stress Disorder
Study of 3,4-Methylenedioxymethamphetamine-assisted Psychotherapy in People With Posttraumatic Stress Disorder
This study will examine MDMA-assisted psychotherapy in individuals aged 18 years or older diagnosed with PTSD, with PTSD symptoms not improving after trying at least one treatment.
- Trial name
- NCT00353938
- Testing
- 3,4-methylenedioxymethamphetamine (125 mg), 3,4-methyelendioxymethamphetamine (25 mg), Therapy
- Where
- Switzerland
- Volunteers
- 14 people
- Sponsor
- Resilient Pharmaceuticals
Schizophrenia
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning.
- Trial name
- NCT04860830
- Testing
- Iclepertin
- Where
- 110 sites in United States, Argentina and 16 more
- Volunteers
- 609 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
An Extension Study to a Clinical Study That Will Continue to Evaluate the Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication
An Extension study to a clinical study that will continue to evaluate the effectiveness and safety of SEP-363856 in people with schizophrenia that switch to SEP-363856 from their current antipsychotic medication.
- Trial name
- NCT05741528
- Testing
- SEP-363856
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia, Alzheimer Disease
All About Me: An Intervention to Ease the Transition to Long Term Care
This Phase I study will involve initial development and evaluation of an innovative cross-platform software app called All About Me (AAM), which will consist of Serious Digital Health Games (SDHGs) for PWD.
- Conditions
- Dementia, Alzheimer Disease, Dementia, Vascular, Dementia, Mixed
- Trial name
- AAM (NCT05516134)
- Testing
- SAFE at Home
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Hopeful Aging
Schizophrenia
A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. Participants in the study will either receive the drug being studied or a placebo.
- Trial name
- NCT04072354
- Testing
- SEP-363856 50mg, SEP-363856 75mg
- Where
- 53 sites in United States, Bulgaria and 4 more
- Volunteers
- 463 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Engagement, Patient, Mood
SimpleC Wellness Platform With Social Robot Interaction
This implementation study will be conducted to test a Socially-Assistive Robot (SAR) system for residents in an Assisted Living environment. The goal of the SAR system is to enhance social engagement and connectedness.
- Conditions
- Engagement, Patient, Mood, Quality of Life, Aging
- Trial name
- NCT05296239
- Testing
- SimpleC Wellness Platform with Social Robot Interaction
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- SimpleC, LLC
Depressive Disorder, Major
A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
To assess the effect of a single dose of BI 1358894 compared to placebo on BOLD responses in modulating brain processing of emotional and cognitive stimuli on the amygdala and related brain structure using fMRI in in unmedicated…
- Trial name
- NCT03854578
- Testing
- BI 1358894, Citalopram
- Where
- Germany
- Volunteers
- 73 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim